According to a recent diabetes news report, anti- cholesterol drug fenofibrate could dramatically lower the risk of people with diabetes facing amputation, by as much as 36 per cent in some instances.
A special diabetes edition of The Lancet published the study, which was conducted in Australia. The 5-year trial involved almost 10,000 people with diabetes being given fenofibrate.
The team, from the National Health and Medical Research Council Clinical Trials Centre in the University of Sydney, Australia, reportedly commented: "Treatment with fenofibrate was associated with a lower risk of amputations, particularly minor amputations (below the ankle). These findings could lead to a change in standard treatment for the prevention of diabetes-related lower-limb amputations."
Reports suggest that a diabetes related amputation happens every 30 seconds around the world.
Diabetes amputation risk cut by cholesterol drug
Fri, 22 May 2009
Recommended links
Diabetes newsletterDiabetes financial services
Diabetes - MyLife
Diabetes tool could lower hospital stay
Walnuts and diabetes
Whats new on diabetes
Race a factor in diabetes amputation
Diabetes amputation levels climbing
Amputation solution for diabetes one step closer
Diabetes amputation solution
Diabetes amputations could be lowered
Diabetes study predicts amputation infection risk
Vigilant diabetes foot care to avoid amputation
Diabetes-related amputation is not necessary
Diabetes study shows amputation risk
Limb Amputation May be Prevented for Diabetics
Join us